Saturday 17 October 2026
Export LIMN’s income statement to Excel — free account
Liminatus Pharma Inc.
LIMN Healthcare Biotechnology
In the quarter to June 2026, EPS fell 717.0%, free cash flow grew 89.0% and total debt was flat, each against the same quarter a year earlier.
3.04
0.17
−5.30%
Follow LIMN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+6 more quarters Free account |
0.42 | 0.05 | 0.96 | 1.12 |
Net Debt/EBITDA |
(1.02) | (1.25) | 0.42 | 1.14 | |
Debt/Assets |
107.46% | 281.30% | 51.70% | 42.38% | |
Debt/Equity |
(0.88) | (0.15) | (10.88) | 4.80 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.33 | 0.05 | 1.79 | 0.69 | |
Capex/Depreciation |
(21.83) | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(36.71) | (46.29) | (59.19) | (73.35) | |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.14) | (0.81) | (2.80) | (1.00) | |
Cash per Share |
1.34 | 0.71 | 2.65 | 3.12 | |
Shareholders Equity per Share |
(3.05) | (20.66) | (0.18) | 0.31 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(3.05) | (20.66) | (0.18) | 0.31 | |
Free Cash Flow |
(0.61) | (0.39) | (2.02) | (0.97) | |
Working Capital |
(1.66) | (9.80) | (0.11) | 0.35 | |
Capital Expenditures |
(0.01) | 0.00 | — | — | |
Net Current Asset Value |
(1.78) | (9.83) | (0.14) | 0.29 | |
| Other line items | |||||
Quick Ratio |
0.25 | 0.03 | 0.66 | 0.99 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.11) | (0.81) | (2.80) | (1.00) | |
Capex per Share |
(0.02) | 0.00 | 0.00 | 0.00 | |
Average Payables |
— | — | 1.01 | 0.54 | |
Average Assets |
0.67 | 2.96 | 4.10 | 2.66 | |
Average Common Equity |
— | (14.58) | (0.07) | (4.25) | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates